{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:06:34Z","timestamp":1767146794135,"version":"build-2238731810"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.jcv.2015.02.001","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T12:51:45Z","timestamp":1424091105000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN\/RBV+daclatasvir: A case study using ultra deep pyrosequencing"],"prefix":"10.1016","volume":"66","author":[{"given":"Barbara","family":"Bartolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Giombini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catia","family":"Sias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Taibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Montalbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"D\u2019Offizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nannan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rosa","family":"Garbuglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Capobianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"January (1)","key":"10.1016\/j.jcv.2015.02.001_bib0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"Jan 61","author":"Messina","year":"2015","journal-title":"Hepatol. Hepatol."},{"key":"10.1016\/j.jcv.2015.02.001_bib0010","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","article-title":"HCV burden of infection in Egypt: results from a nationwide survey","volume":"19","author":"Guerra","year":"2012","journal-title":"J. Viral Hepatitis"},{"key":"10.1016\/j.jcv.2015.02.001_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.26719\/2010.16.2.134","article-title":"Sentinel surveillance for patients with acute hepatitis in Egypt, 2001\u201304","volume":"16","author":"Talaat","year":"2010","journal-title":"East Mediterr. Health J."},{"key":"10.1016\/j.jcv.2015.02.001_bib0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/jmv.20392","article-title":"Surveillance of acute hepatitis C in Cairo, Egypt","volume":"76","author":"El Gaafary","year":"2005","journal-title":"J. Med. Virol"},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2015.02.001_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1478-3231.2010.02385.x","article-title":"Hepatitis C virus genotype 4 therapy: progress and challenges","volume":"31","author":"Kamal","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.jcv.2015.02.001_bib0030","series-title":"Virologie European Congress of Virology","article-title":"Molecular and epidemiological profiles of Hepatitis C virus genotype 4 in Regione Lazio, Italy","author":"Garbuglia","year":"2013"},{"key":"10.1016\/j.jcv.2015.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/infdis\/jit274","article-title":"Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial","volume":"208","author":"Benhamou","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.02.001_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cld.2012.09.006","article-title":"HCV NS5A inhibitors in development","volume":"17","author":"Suk-Fong Lok","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jcv.2015.02.001_bib0045","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.06169-11","article-title":"In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.001_bib0050","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.001_bib0055","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.02.001_bib0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.02.001_bib0065","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"McPhee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.02.001_bib0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Karino","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2015.02.001_bib0075","first-page":"2","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"2","author":"McPhee","year":"2014","journal-title":"Antivir. Ther."},{"issue":"Suppl","key":"10.1016\/j.jcv.2015.02.001_bib0080","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/S0168-8278(13)61211-8","article-title":"Pre-existence, emergence and persistence of HCV genotype 4 NS5A resitance variants from the phase 2B COMMAND-1 study: daclatasvir plus peginterferon-alfa\/ribavirin in treatment-na\u00efve patients","volume":"58","author":"McPhee","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2015.02.001_bib0085","first-page":"1","article-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study","volume":"0","author":"H\u00e9zode","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jcv.2015.02.001_bib0090","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.dld.2013.11.006","article-title":"No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance","volume":"46","author":"Visco-Comandini","year":"2014","journal-title":"Dig. Liver Dis."},{"issue":"March 1 (5)","key":"10.1016\/j.jcv.2015.02.001_bib0095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.02.001_bib0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.02.001_bib0105","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.001_bib0110","series-title":"Proceeding of the American association for the Study of Liver Diseases AASLD","article-title":"Identification and treatment of multiple subtypes of HCV genotype 4 in the PEARL-I study with ombitasvir and ABT-450\/r\u2009\u00b1ribavirin","author":"Schnell","year":"2015"},{"key":"10.1016\/j.jcv.2015.02.001_bib0115","series-title":"Proceeding of the American association for the Study of Liver Diseases AASLD","article-title":"NS5A variability and dynamics of resistance-associated mutations in HCV genotype 4 patients, naive to treatment receiving triple therapy with DACLATASVIR+PEG-IFN\/RBV, assessed by ultra deep sequencing","author":"Bartolini","year":"2015"},{"issue":"August (8)","key":"10.1016\/j.jcv.2015.02.001_bib0120","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1128\/AAC.02777-13","article-title":"In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus","volume":"58","author":"Bilello","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.001_bib0125","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/hep.25924","article-title":"Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders","volume":"57","author":"Galmozzi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.02.001_bib0130","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1128\/AAC.02068-13","article-title":"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin","volume":"58","author":"Murakami","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.02.001_bib0135","first-page":"5","article-title":"Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection","volume":"2","author":"Miura","year":"2014","journal-title":"Hepatol. Res."}],"updated-by":[{"DOI":"10.1016\/j.jcv.2015.05.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000}}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T19:46:57Z","timestamp":1566330417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":27,"alternative-id":["S1386653215000384"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.02.001","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN\/RBV+daclatasvir: A case study using ultra deep pyrosequencing","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}